1233501-57-9

Usage

Uses

Used in Pharmaceutical Synthesis:
4-ethynyl-3-fluorobenzenaMine is used as a key intermediate in the synthesis of various pharmaceuticals, leveraging its strong electron-withdrawing properties to facilitate a range of organic reactions that contribute to the development of new drugs.
Used in Organic Chemistry:
In the realm of organic chemistry, 4-ethynyl-3-fluorobenzenaMine is utilized as a ligand in catalysts, enabling a variety of chemical transformations that are crucial for the advancement of organic synthesis techniques.
Used in Material Science:
4-ethynyl-3-fluorobenzenaMine's unique properties also make it a valuable component in the field of material science, where it can be incorporated into the development of new materials with specific properties tailored for various applications.

Upstream product

• 2146146-58-7 3-fluoro-4-[(trimethylsilyl)ethynyl]aniline 
• 656-66-6 3-fluoro-4-iodoaniline 

Relevant academic research and scientific papers

General and efficient synthesis of polyfluorinated 2-aminotolans and 2-arylindoles

It was established here that cross-coupling of polyfluorinated 2-iodoanilines with arylacetylenes in MeCN in the presence catalytic amounts of Pd(PPh3)2Cl2, CuI and Et3N produces the corresponding 2-aminotolans although their yields are decreased from 98% to 40% with increasing fluorination of the substrates. It was shown that the 2-aminotolans with six or fewer fluorine atoms in their rings can be heterocyclised by heating in ethanol containing p-TSA to produce the corresponding polyfluorinated indoles. Cyclisation of tolans containing larger numbers of fluorine atoms in their rings proceeds most efficiently in the presence of KOH, resulting in 2-phenylindoles containing the current maximum of eight fluorine atoms.

LpxC Inhibitors: Design, Synthesis, and Biological Evaluation of Oxazolidinones as Gram-negative Antibacterial Agents

Herein we report a scaffold-hopping approach to identify a new scaffold with a zinc binding headgroup. Structural information was used to give novel oxazolidinone-based LpxC inhibitors. In particular, the most potent compound, 23j, showed a low efflux ratio, nanomolar potencies against E. coli LpxC enzyme, and excellent antibacterial activity against E. coli and K. pneumoniae. Computational docking was used to predict the interaction between 23j and E. coli LpxC, suggesting that the interactions with C207 and C63 contribute to the strong activity. These results provide new insights into the design of next-generation LpxC inhibitors.